首页 / 院系成果 / 成果详情页

Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study 期刊论文

编号：

87e6ebb4-2b72-4ad5-99df-c33114639e03
作者：

Liu, Fengyong^[1] Meng, Zhiqiang^[2] Shao, Guoliang^[3] Wang, Jianhua^[4] Wang, Zhijun^[1] Yang, Jijin^[5] Yip, Christina S. M.^[6] He, Dongfeng^[6]
语种：

English
期刊：

MOLECULAR BIOLOGY REPORTS ISSN：0301-4851 2017 年 44 卷 1 期 (149 - 158) ; FEB
收录：
关键词：

Hepatocellular carcinoma Unresectable Advanced Sorafenib TACE, transarterial chemoembolization Observational studies Survival, neoplasm staging
摘要：

To analyze safety and efficacy of patterns of sorafenib and TACE therapy under real-life clinical practice conditions. A total of 338 Chinese patients with unresectable hepatocellular carcinoma (HCC) from the international database of the GIDEON non-interventional trial were included in this analysis. Endpoints were overall survival (OS), progression-free survival (PFS), time to progression (TTP) and safety. Two major patterns in the use of sorafenib observed in current Chinese clinical practice were: sorafenib administration subsequent to transarterial chemoembolization (TACE) treatment (n = 226, 66.9%) and sorafenib administration concomitant to TACE (n = 80, 35.4%). Patients receiving TACE prior to sorafenib had worse liver function (43.8% BCLC stage Cat diagnosis and 62.1% BCLC stage C at study entry) than those receiving TACE concomitant to sorefenib (35.0% BCLC stage C at diagnosis and 51.3% BCLC stage three at study entry). For patients undergoing prior TACE and concomitant TACE treatment, median OS time was 354 days vs. 608 days, PFS time was 168 days vs. 201 days, and TTP was 214 days vs. 205 days; and the percentage of patients who experienced drug-related adverse effects after sorafenib therapy in these two groups were 33.3 and 50.0%, respectively. Sorafenib treatment is usually administered in cases of tumor progression or poor liver function status after TACE treatment in China. Under such conditions, patients still gained a relatively satisfactory survival outcome. In addition, the present study suggests that concomitant sorafenib and TACE treatments may lead to a better prognosis, although differences in baseline characteristics may have contributed in part to the better outcomes.
推荐引用方式
GB/T 7714：

Liu Fengyong,Meng Zhiqiang,Shao Guoliang, et al. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study [J].MOLECULAR BIOLOGY REPORTS,2017,44(1):149-158.
APA：

Liu Fengyong,Meng Zhiqiang,Shao Guoliang,Wang Jianhua,&He Dongfeng.(2017).Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study .MOLECULAR BIOLOGY REPORTS,44(1):149-158.
MLA：

Liu Fengyong, et al. "Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study" .MOLECULAR BIOLOGY REPORTS 44,1(2017):149-158.

浏览次数：10  下载次数：0

分享到：

浏览次数：10

下载次数：0

打印次数：0